Amylin Pharmaceuticals, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases.
Amylin Pharmaceuticals was a biopharmaceutical company based in San Diego, CA, that was founded in 1987.The company was engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases.
Amylin Pharmaceuticals is a biopharmaceutical firm located in San Diego, California, with over 1,000 employees in the US. Amylin has developed and gained approval for two first-in-class medicines for the treatment of type I and type II diabetes, Symlin (pramlintide acetate) injection and Byetta (exenatide) injection.
Amylin Pharmaceuticals, Inc. Amylin Pharmaceuticals, Inc. is now part of AstraZeneca. (December 2013) See: AstraZeneca
AstraZeneca and Bristol-Myers Squibb anticipate that subject to local consultation and legislation, approximately 4,100 Bristol-Myers Squibb employees dedicated to the diabetes business, including those at Amylin, will eventually transition to AstraZeneca.
Bristol-Myers Squibb is a global biopharma company dedicated to discovering, developing and delivering innovative medicines to patients with serious diseases.